Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)

Thomas Bachelot Cristian Villanueva; Melanie Royce; Marc Debled; Felipe Melo Cruz; Roberto Hegg; Thomas Brechenmacher; Corinne Manlius; Francois Ringeisen; Fatima Cardoso; Advanced Breast Cancer Third International Consensus Conference (3. 2015 Lisbon, Portugal)

The Breast Edinburgh v. 24, n. supl. 3, p. S41, abst. PO56, 2015

Edinburgh 2015

Acesso online. A biblioteca também possui exemplares impressos.